GSK-2793660

Names

[ Name ]:
GSK-2793660

Biological Activity

[Description]:

GSK-2793660 is an oral, irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 can be used for the research of bronchiectasis[1][2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Metabolic Enzyme/Protease >> Cathepsin

[Target]

Cathepsin C (CTSC)[1][2]

[In Vivo]

GSK-2793660 is a cathepsin C (also known as dipeptidyl peptidase I enzyme) inhibitor for the reaearch of cystic fibrosis, non-cystic fibrosis bronchiectasis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and bronchiectasis[1].

[References]

[1]. Szcześniak P, et al. The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. J Org Chem. 2016 Feb 5;81(3):1057-74.

[2]. Miller BE, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017 Dec;83(12):2813-2820.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₀H₂₇N₃O₃

[ Molecular Weight ]:
357.45

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.